John Fromson
Director/Miembro de la Junta en NeuroTargets Ltd. .
Perfil
John Fromson has more than 35 years experience as a scientist, manager and entrepreneur in the healthcare and chemistry fields.
He worked for 18 years at ICI Pharmaceuticals and Hoechst and, in particular, as Research Director for Hoechst Pharmaceuticals in charge of developing three major products.
He subsequently spent 5 years at Hazleton, a contract services organisation in the pharmaceutical industry.
In 1992, he became Vice-President of Clinical Development at Vanguard Medica, where he played a key role in the company’s IPO and the development of the anti-migraine drug, frovatriptan.
In 1998, he founded Devco Pharmaceuticals, a company developing neurology therapeutics.
In 2002, he became Executive Chairman of Ultrafine, a company specialised in providing chemistry services to the pharmaceutical industry.
During this period he carried out a major, successful restructuring operation which led to the sale of the company to Sigma Aldrich within two years.
In 2006, he became a shareholder and Executive Chairman of Dextra Laboratories, a company manufacturing chemistry products for the pharmaceutical industry.
In 2007, following the successful completion of a restructuring programme and a significant increase in annual revenues, the company was sold to Summit Group plc, listed on AIM.
Mr. Fromson has a BSc degree in Chemistry, and a PhD from Queen’s University (Belfast).
Cargos activos de John Fromson
Empresas | Cargo | Inicio |
---|---|---|
NeuroTargets Ltd.
NeuroTargets Ltd. Pharmaceuticals: MajorHealth Technology NeuroTargets, Inc. develops novel therapeutic products. It discovers and develops new drugs for neurological diseases. The company develops products in the fields of diabetic neuropathy, pain resulting from nerve damage, spinal cord injuries and other trauma, and brain diseases associated with cognitive impairment such as stroke and Alzheimer's disease. NeuroTargets was founded in 1999 and is located at Guildford, UK. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de John Fromson.
Empresas | Cargo | Fin |
---|---|---|
Generis Capital Partners SAS
Generis Capital Partners SAS Investment ManagersFinance Generis Capital Partners SAS (GCP) is an independent venture capital and private equity firm founded in 2008 by Thibaut de Roux. The firm is headquartered in Paris, France. | Inversor de Capital Privado | 31/12/2010 |
Ultrafine Ltd. (Gillingham)
Ultrafine Ltd. (Gillingham) Miscellaneous Commercial ServicesCommercial Services Ultrafine Ltd. researches and develops chemical compounds. The company was founded on March 12, 2004 and is headquartered in Gillingham, the United Kingdom. | Presidente | - |
Vanguard Medica Plc | Corporate Officer/Principal | - |
Innovata Ltd.
Innovata Ltd. Pharmaceuticals: MajorHealth Technology Innovata Ltd. researches and develops pharmaceutical and medical products. It develops pulmonary products for the treatment of respiratory disorders and other serious diseases. The company was founded on July 20,1987 and is headquartered in Nottingham, the United Kingdom. | Director/Miembro de la Junta | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 5 |
---|---|
Vanguard Medica Plc | Commercial Services |
Ultrafine Ltd. (Gillingham)
Ultrafine Ltd. (Gillingham) Miscellaneous Commercial ServicesCommercial Services Ultrafine Ltd. researches and develops chemical compounds. The company was founded on March 12, 2004 and is headquartered in Gillingham, the United Kingdom. | Commercial Services |
NeuroTargets Ltd.
NeuroTargets Ltd. Pharmaceuticals: MajorHealth Technology NeuroTargets, Inc. develops novel therapeutic products. It discovers and develops new drugs for neurological diseases. The company develops products in the fields of diabetic neuropathy, pain resulting from nerve damage, spinal cord injuries and other trauma, and brain diseases associated with cognitive impairment such as stroke and Alzheimer's disease. NeuroTargets was founded in 1999 and is located at Guildford, UK. | Health Technology |
Innovata Ltd.
Innovata Ltd. Pharmaceuticals: MajorHealth Technology Innovata Ltd. researches and develops pharmaceutical and medical products. It develops pulmonary products for the treatment of respiratory disorders and other serious diseases. The company was founded on July 20,1987 and is headquartered in Nottingham, the United Kingdom. | Health Technology |
Generis Capital Partners SAS
Generis Capital Partners SAS Investment ManagersFinance Generis Capital Partners SAS (GCP) is an independent venture capital and private equity firm founded in 2008 by Thibaut de Roux. The firm is headquartered in Paris, France. | Finance |
- Bolsa de valores
- Insiders
- John Fromson